Dendritic cell–derived exosomes for cancer therapy

Abstract : DC-derived exosomes (Dex) are nanometer-sized membrane vesicles that are secreted by the sentinel antigen-presenting cells of the immune system: DCs. Like DCs, the molecular composition of Dex includes surface expression of functional MHC-peptide complexes, costimulatory molecules, and other components that interact with immune cells. Dex have the potential to facilitate immune cell–dependent tumor rejection and have distinct advantages over cell-based immunotherapies involving DCs. Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing the feasibility and safety of the approach, as well as the propensity of these nanovesicles to mediate T and NK cell–based immune responses in patients. This Review will evaluate the interactions of Dex with immune cells, their clinical progress, and the future of Dex immunotherapy for cancer.
Document type :
Journal articles
Complete list of metadatas

Cited literature [2 references]  Display  Hide  Download
Contributor : Gestionnaire Hal-Upmc <>
Submitted on : Monday, May 2, 2016 - 4:59:07 PM
Last modification on : Monday, February 10, 2020 - 6:14:06 PM
Long-term archiving on: Tuesday, November 15, 2016 - 7:15:26 PM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License



Jonathan M. Pitt, Fabrice André, Sebastian Amigorena, Jean-Charles Soria, Alexander Eggermont, et al.. Dendritic cell–derived exosomes for cancer therapy. Journal of Clinical Investigation, American Society for Clinical Investigation, 2016, 126 (4), pp.1224-1232. ⟨10.1172/JCI81137⟩. ⟨hal-01310534⟩



Record views


Files downloads